Skip to main content
. Author manuscript; available in PMC: 2016 Jun 15.
Published in final edited form as: Cancer. 2015 Mar 10;121(12):1937–1948. doi: 10.1002/cncr.29310

Figure 2.

Figure 2

Chemotherapy with or without trastuzumab received between 2000 and 2009 (A) the percentage of patients with human epidermal growth factor receptor 2 (HER2)-positive disease receiving chemotherapy and (B) patients with HER2-negative disease, subdivided into (B1) the percentage of patients with HER2-negative, hormone receptor (HR)-positive disease receiving chemotherapy and (B2) the percentage of patients with HER2-negative/HR-negative disease receiving chemotherapy.